Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN. (Q42236065)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 February 2014

Language	Label	Description	Also known as
English	Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.	scientific article published on 20 February 2014

Statements

scholarly article

1 reference

Europe PubMed Central

19 October 2017

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN. (English)

1 reference

Europe PubMed Central

19 October 2017

chronic hepatitis B

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Maryline Bourgine

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Daniel Scott-Algara

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

H Fontaine

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

S Kahi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

C Chazallon

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

A Varaut

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

C Buffet

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

O Godon

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

J F Meritet

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Y Saïdi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

M L Michel

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

J P Aboulker

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

S Pol

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

ANRS HB02 study group

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

language of work or name

0 references

publication date

20 February 2014

1 reference

Europe PubMed Central

19 October 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

64

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

139-147

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24555998%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Epidemiology of viral hepatitis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Therapeutic vaccination against chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Side effects of long-term oral antiviral therapy for hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Immunology of hepatitis B virus and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305707

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42236065&oldid=1716798882"